Earticle

초록

영어

Nanoparticles have been extensively investigated for targeted delivery of anticancer drug. Especially, chitosan based nanoparticles is believed as a promising carriers for cancer chemotherapy and imaging. Due to superior biocompatibility, non-cytotoxic, and biologically active properties, chitosan is frequently used as a biomedical materials and drug carriers. Furthermore, chitosan is regarded as an ideal vehicle for delivery of anionic drug or DNA drug due to its positive ionic proeprties. Chitosan is used to make polyion complexes with anionic drug such as all-trans retinoic acid (RA) and these ionic complexes can form nanoparticles in aqueous media We prepared RA-incorporated glycol chitosan (GC) nanoparticles by simple mixing RA into the GC aqueous solution through ion complex formation between RA and GC. Particle sizes of RA-incorporated GC nanoparticles were approximately 300~500 nm. Lyophilized nanoparticles were simply reconstituted into aqueous solution in spite of absence of cryoprotectants. RA-incorporated GC nanoparticles showed similar cytotoxicity against cholangiocarcinoma cells. Furthermore, RA-incorporated GC nanoparticles showed enhanced anti-invasive capacity and anti-migration capacity against HuCC-T1 cholangiocarcinoma cells. We suggest that RA-incorporated GC nanoparticles are promising vehicles for antitumor drug delivery.

저자

• Cy-Hyun Kim [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]
• Do-Hyung Kim [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]
• Hye-Myung Lee [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]
• Tae-Won Kwak [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]
• Young-IL Jeong [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]
• Chung-Wook Chung [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]
• Dae-Hwan Kang [ Nat. Res. & Dev. Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, Gyeongnam 626-770, Republic of Korea Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, Asansi, Chungnam, 336-708, Korea ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국당과학회 학술대회

• 간기

  연간

• 수록기간

  2006~2022

• 십진분류

  KDC 517 DDC 614